ArticleAmerican journal of hematology2024
Correction to "Benefit of axicabtagene ciloleucel vs chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy".
No numbers read from the abstract.